Evidence-Based Clinical Practice Guideline: Reduction Mammaplasty
Evidence-based Clinical Practice Guideline: Reduction Mammaplasty INTRODUCTION Conflict of Interest Rationale and Goals All contributors and preparers of the guideline, including the ASPS Female symptomatic breast hypertrophy can have negative Health Policy Committee and staff, disclosed any conflicts of interest physical and psychosocial manifestations. As a consequence, via an on-line disclosure reporting database: female symptomatic breast hypertrophy is now recognized as a Loree Kalliainen, M.D., Chair, has no additional disclosures; medical condition that requires therapeutic management. Given Dale C. Vidal, M.D., Past Chair, has a Consultant relationship the lack of a lasting non-operative treatment for this condition, with Mentor Corporation/Ethicon/J&J; Peter Aldea, M.D., has no female symptomatic breast hypertrophy is most often managed by additional disclosures; Steven Bonawitz, M.D., has no additional reduction mammaplasty, which effectively improves the physical disclosures; Gary Culbertson, M.D., has no additional disclosures; and psychological manifestations of the condition. The aim of Kevin Chung, M.D., has no additional disclosures; Lynn Damitz, this document is to address the assessment of symptomatic breast M.D., has no additional disclosures; Leland Deane, M.D., has a hypertrophy, its treatment through reduction mammaplasty, and consultant relationship with Covidien; Richard Greco, M.D., has a to develop a set of recommendations that fairly reflect current speaker relationship with Mentor Corporation/Ethicon/J&J and a accepted medical standards. These guidelines were developed from shareholder relationship with Obagi Medical Products; Christopher a comprehensive review of the scientific literature and reflect the Hussussian, M.D., has no additional disclosures; Sami Khan, M.D., consensus of the Health Policy Committee of the American Society of ® has no additional disclosures; Bill Kortesis, M.D., has no additional Plastic Surgeons.
[Show full text]